重组全人源抗PD-L1抗体 (桂林三金药业)(Recombinant human anti-PD-L1 monoclonal antibody(Guilin Sanjin Pharmaceutical Co., Ltd.)) - 药物靶点：PDL1_在研适应症：肾肿瘤，肌层浸润性膀胱癌，阴茎肿瘤_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

LDP、lesabelimab、ADG104

+ [1]

靶点

PDL1

作用方式

抑制剂

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床2期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 631426828H

来源: *****

Sequence Code 631426829L

来源: *****

关联

5

项与重组全人源抗PD-L1抗体 (桂林三金药业) 相关的临床试验

CTR20202643

/ Active, not recruiting临床1期

评价全人源抗PD -L1抗体注射液（LDP）联合重组抗EGFR人鼠嵌合单克隆抗体注射液（CDP1）在晚期恶性肿瘤患者中的探索性临床研究

评估LDP联合CDP1治疗晚期恶性肿瘤患者的安全性，确定临床试验推荐剂量。

开始日期2021-01-20

申办/合作机构

宝船生物医药科技（上海）有限公司

CTR20202642

/ Active, not recruiting临床1期

评价全人源抗PD -L1抗体注射液（LDP）联合重组抗EGFR人鼠嵌合单克隆抗体注射液（CDP1）在晚期恶性肿瘤患者中的探索性临床研究

评估LDP联合CDP1治疗晚期恶性肿瘤患者的安全性，确定临床试验推荐剂量。

开始日期2021-01-20

申办/合作机构

宝船生物医药科技（上海）有限公司

CTR20201949

/ Active, not recruiting临床2期

全人源抗PD-L1抗体注射液（LDP）治疗泌尿及男性生殖系统肿瘤有效性和安全性的、单臂、开放、多中心、II期临床研究

评价全人源抗PD-L1抗体注射液（LDP）在肌层浸润性膀胱癌新辅助、晚期非透明细胞肾癌和晚期阴茎癌受试者中的有效性和安全性。

开始日期2021-01-07

申办/合作机构

桂林三金药业股份有限公司

[+3]

100 项与重组全人源抗PD-L1抗体 (桂林三金药业) 相关的临床结果

登录后查看更多信息

100 项与重组全人源抗PD-L1抗体 (桂林三金药业) 相关的转化医学

登录后查看更多信息

100 项与重组全人源抗PD-L1抗体 (桂林三金药业) 相关的专利（医药）

登录后查看更多信息

200

项与重组全人源抗PD-L1抗体 (桂林三金药业) 相关的文献（医药）

2025-05-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

The impact of ecological pressure caused by toxic lignin metabolites on microbial function transformation during composting

Article

作者: Wu, Junqiu ; Zhang, Chunhao ; Lu, Yun ; Li, Zonglin ; Huang, Fuli ; Qiao, Xingyu

Environmental stress coexists with microbial interactions during composting, temperature was thought to be the main stress, the toxic stress caused by aromatic compounds was often overlooked. Herein, lignin and lignin degradation products (LDP) were used alone or in combination to culture the compost microbial community, which manually delineated 32 niches to explore the effects of toxic stress on microbe and their responses. Results showed that the toxicity of LDP significantly changed the distribution of microbial community. Then, microorganisms were divided into three groups: specialist showed high diversity and low abundance, responsible for the metabolism of toxic macromolecules, with detoxification effect. Generalist exhibited high abundance and diversity, which mainly changed metabolic byproducts to cellular energy and sustaining the survival of microorganisms. Accordingly, these characteristics were the survival strategies of microbial communities to harmonize the toxic stress in different ecological niche. While the results of the lignin metabolic catalog have confirmed the metabolic tendency of different microorganism in the metabolic module. Finally, this study help to further understand microbe survival strategies in aromatic pollutants composting, which may be possible to accelerate or alter the composting process by manipulating the microbial community.

2025-03-01·JOURNAL OF PROSTHETIC DENTISTRY

Mechanical properties of 3D printed denture base polymers

Article

作者: Hoffmann, Moritz ; Mayinger, Felicitas ; Coldea, Andrea ; Meinen, John ; Stawarczyk, Bogna

STATEMENT OF PROBLEM:

Studies on the mechanical properties of 3-dimensionally (3D) printed denture base polymers with appropriate test methods are lacking.

PURPOSE:

The purpose of this in vitro study was to determine the flexural strength (σ_f), elastic modulus (E), fracture toughness (K_IC), work of fracture (ω_e), and Martens hardness (HM) of 3D printed denture base polymers and to compare them with an injection molded material.

MATERIAL AND METHODS:

Three resins for additive (Lucitone Digital Print, LDP; Flexcera Base, FCB and an experimental material, EXP) and 1 for injection molding (IvoBase Hybrid, IBH) fabrication were analyzed. Standardized specimens were fabricated, polished, tempered, and thermal cycled (5 °C to 55 °C) before testing for σ_f, E, K_IC, ω_e, and HM. The results were explored by global analysis (α=.05). The Kolmogorov-Smirnov test was used to test for data distribution. Parametric and nonparametric tests followed by pairwise comparison were applied to test for differences between groups.

RESULTS:

The σf, E, and HM of 3D printed polymers were significantly lower than those of the injection molded, both for the tempered and aged groups. The σf was lowest for FCB and highest for IBH in the tempered state. The K_IC and ω_e of the tempered EXP and IBH groups were lower compared with those of FCB and LDP. After aging, EXP, FCB, and IBH presented K_IC in the same range, but it was lower than for LDP. Compared with the printable polymers, the control group IBH was not affected by artificial aging.

CONCLUSIONS:

The σ_f, E, and HM of printable polymers were lower than those of the control group, and specimens did not fracture in bend testing. In contrast, K_IC and ω_e were the highest for a printable polymer. Therefore, tension tests should be considered when testing ductile materials.

2025-03-01·LUMINESCENCE

Trio‐Colored Appraisal of Microwave‐Assisted Synthesis of Carbon Quantum Dots as a Fluorescence Turn Off Nanoprobe for Analyzing Ledipasvir in Tablets and Rat Feces: Study of Silymarin Impact on Excretion Recovery

Article

作者: Ragab, Mahmoud A. ; Aboras, Sara I. ; Ahmed, Aya R. ; Elbordiny, Haydi S. ; Belal, Tarek S. ; Elnaggar, Mai M.

ABSTRACT:

The current work offers a rigorous way for the microwave‐assisted synthesis of N and S doped carbon quantum dots (QDs). The latter are deemed highly sensitive and selective fluorescence sensors that were widely investigated in pharmaceutical analysis. Quenching of luminescence of the prepared QDs in lab fabricated sensor at λ emission = 418 nm after excitation at 370 nm was implemented to quantify the anti‐HCV drug Ledipasvir (LDP). LDP showed a linear response within the dynamic range of 1–40 μM. The calculated LDP detection and quantification limits were 313.06 and 948.67 nM, respectively. Besides the analysis of LDP in bulk and commercial dosage form, the scope of application extended to evaluate the effect of the nutraceutical silymarin (liver support) on the excretion of LDP in rat feces. The compliance with the green and white analytical chemistry fundamentals is comprehensively investigated and compared with selected versatile reported procedures. Numerous prevalent metrics, namely, analytical eco‐scale, AGREE, RGB12, RGB fast, BAGI, and complex GAPI, were employed. Our developed fluorometric procedure demonstrated great sensitivity, selectivity, and functionality that outperformed other sophisticated platforms. Thus, the utility of the depicted procedure in pharmaceutical analysis and studying pharmacokinetics aspects is profoundly proven.

1

项与重组全人源抗PD-L1抗体 (桂林三金药业) 相关的新闻（医药）

2021-01-21

·医药合作投融资联盟

重磅！天演药业提交美股IPO申请，拟募资1.25亿美元

2021年1月19日，据美国纳斯达克官网显示，正在中国开发抗体癌症免疫疗法的Adagene（天演药业）向美国证券交易委员会提交了F-1申请，希望通过首次公开募股筹集至多1.25亿美元（F-1文件例行融资规模不代表实际募资金额）。联席承销商是高盛、摩根士丹利，Jefferies，华兴资本。天演药业2014年成立至今已经累计融资超过1.5亿美元，其中包括2018年3月完成了5000万美元C轮融资，2020年1月完成了6900万美元D轮融资，猜测估值5亿美元左右。天演药业目前合作伙伴有药明生物、宝船生物、ADC Therapeutics 、Sanjin等。这是今年继亘喜生物在美股IPO上市后，拓臻生物提交IPO申请（8700万美元融资后，拓臻生物提交美股IPO申请，拟募资1亿美元！）后第三家来自中国的biotech去纳斯达克上市申请。 Adagene（天演药业）投资机构在将计算生物学和人工智能相结合的强大平台的驱动下，该公司的AI-Powered DPL平台探索了蛋白质序列的动态构象多样性，尤其是抗体序列的灵活结合位点，以此作为发现抗体药物的新范例。动态精密库平台由三种专有技术组成，这些专有技术针对基于抗体的治疗方式的三个关键属性进行了定制： NEObody™可以生成具有动态结合位点的抗体，这些结合位点通过新型MOA（称为NEO抗体）在动力学上适应独特的表位。 SAFEbody™能够生成被掩盖的抗体和NEO抗体，这些抗体和NEO抗体被设计为在肿瘤微环境或TME中选择性激活，从而有可能限制正常组织中的靶标非肿瘤毒性，称之为SAFE抗体。 POWERbody™将我们的SAFEbody技术应用于强大的基于抗体的模式，例如创建新的SAFE双特异性T细胞衔接子，SAFE抗体-药物偶联物或SAFE ADC或旨在超越传统单特异性抗体治疗功效的抗体。 Notes: 1 NEO, SAFE and POWER refer to the NEObodyTM, SAFEbodyTM and POWERbodyTM respectively* The ADG104 Phase Ib/II clinical trial is conducted by our partner, Sanjin Adagene专门构建的技术平台已经产生了潜在的具有独特MOA的一流产品管线。 ADG106：领先的NEObody™项目是CD137的一流，安全和有效的激动剂，正在对晚期/转移性实体瘤患者进行评估。 ADG126：领先的SAFEbody™项目针对CTLA4，并且在临床前研究中显示，与常用的CTLA4癌症疗法相比，该疗法更安全，更有效，更持久。 ADG116：第二项NEObody项目针对CTLA4的独特表位，目前正在对患有晚期/转移性实体瘤和/或复发/难治性非霍奇金淋巴瘤的患者进行评估。其最先进的NEObody产品候选物ADG106是目前在美国和中国正在进行I期试验的完全人配体阻断激动性抗CD137单克隆抗体。根据新闻来源，ADG106设计用于靶向CD137的独特表位，该表位与临床开发中的其他抗CD137抗体不同。天演药业部分管理团队（来源于官网）版权声明：本文转自医药合作投融资联盟，如不希望被转载的媒体或个人可与我们联系，我们将立即删除【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。点分享点点赞点在看

抗体免疫疗法合作抗体药物偶联物IPO

100 项与重组全人源抗PD-L1抗体 (桂林三金药业) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾肿瘤	临床2期	中国	天演药业（苏州）有限公司	2021-01-07
肾肿瘤	临床2期	中国	桂林三金药业股份有限公司	2021-01-07
肌层浸润性膀胱癌	临床2期	中国	天演药业（苏州）有限公司	2021-01-07
肌层浸润性膀胱癌	临床2期	中国	桂林三金药业股份有限公司	2021-01-07
阴茎肿瘤	临床2期	中国	天演药业（苏州）有限公司	2021-01-07
阴茎肿瘤	临床2期	中国	桂林三金药业股份有限公司	2021-01-07
晚期肾细胞癌	临床2期	中国	宝船生物医药科技（上海）有限公司	2020-09-11
膀胱癌	临床2期	中国	宝船生物医药科技（上海）有限公司	2020-09-11
复发性阴茎癌	临床2期	中国	宝船生物医药科技（上海）有限公司	2020-09-11
晚期癌症	临床1期	中国	天演药业（苏州）有限公司	2019-05-30